An interventional study of Referral strategies in Rheumatic Disease and Arthralgia, sponsored by Maasstad Hospital. Completed at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-03.
Sponsored by Maasstad Hospital · Not applicable, Interventional, and Screening
Among 11 studies in Rheumatic Diseases with a site in Netherlands — 2 open to participants now, 3 under way, none of them phase 3. Rheumatic Diseases · Netherlands.
Among the 11 studies in Rheumatic Diseases with a site in Netherlands, this one is the only one that started in 2017, is one of 6 with no phase, and was the 6th registered.
264 studies on the registry are indexed under Rheumatic Diseases; 60 are open to participants now.
Browse Rheumatic Diseases studies →2 of the 11 studies in Rheumatic Diseases with a site in Netherlands are open now. Recruiting first, the newest first:
Leiden University · Sites in Netherlands
Ages 18+ · Healthy volunteers
Peter den Hollander · Sites in Netherlands
Ages 21–90
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 41 Rheumatic Diseases studies recruiting now, 18 (44%) set no upper age limit and 12 (29%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 544 is above the median of 100 across 167 interventional studies indexed under Rheumatic Diseases.
Median enrollment 75 across the 9 interventional studies, 470 across the 2 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 11 have an industry lead sponsor. The 8 most frequent:
Maasstad Hospital is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Maasstad Hospital has 1 study filed under Rheumatic Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Rheumatic Diseases with a site in Netherlands that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07835256Leiden UniversityEffectiveness of a Combined e-Learning and Virtual Reality Training Program for Healthcare Providers in Rheumatology | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Rheumatic Diseases with a site in Netherlands, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this cluster randomized controlled trial is to improve the number of effectively referred patients with IRD to the rheumatology outpatient clinic with either use of validated referral pro formas or triage of IRD by specialists in a primary care setting compared to usual care. In addition, the investigators want to provide tools for the general practitioner to recognise IRD and improve early referral of patients with IRD, and a cost-effectiveness analysis will be performed to evaluate the decreasing effect on health-care cost.
Rationale: Currently, only 22% of all patients referred to the rheumatologist by primary care are diagnosed with an inflammatory rheumatic disease (IRD). Previous research has shown that structured referral sheets and community-based specialist service improve appropriateness of referrals.
Objective: The aim of this study is to improve the number of effectively referred patients with IRD to the rheumatology outpatient clinic with either use of validated referral pro formas or triage of IRD by specialists in a primary care setting compared to usual care. In addition, the investigators want to provide tools for the general practitioner to recognise IRD and improve early referral of patients with IRD, and a cost-effectiveness analysis will be performed to evaluate the decreasing effect on health-care cost.
Study design: Cluster randomized trial with randomization of general practitioner clinics.
Study population: Primary care patients of 18 years or older who are suspected of an IRD and considered by a GP for referral to a rheumatologist.
Intervention: One group of GPs will use a standardized referral strategy for IRD, another group will consist of triage by a rheumatologist in the local primary care clinic, the third group is usual care.
Main study parameters/endpoints: Percentage of patients diagnosed with an IRD by a rheumatologists after 12 months. In addition, cost effectiveness, quality of life, work participation and health care costs at baseline and after 12 months.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There is no additional risk to participating patients. Patients might benefit from early referral since the referral pro formas point out important aspects of IRD that are frequently overlooked. Patients will be requested to fill in three online questionnaires related to quality of life, work participation and socio-economic costs. There are no additional visits, physical examinations or other tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of electronic structured referral sheets using the algorithms for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis.
Procedure: Referral strategies
Triage by rheumatologist in a primary care setting.
Procedure: Referral strategies
Control group consisting of usual care.
Two referral strategies will be compared to usual care, i.e. the control group. Patients will be followed for one year.
Percentage of appropriate referred patients
Percentage of appropriate referred patients as proportion of all patients referred to the rheumatologist by the general practitioner (GP). Appropriate referred defined as patient diagnosed with an inflammatory rheumatic disease (IRD) as assessed by a rheumatologist, with an IRD as final diagnosis.
Time frame: 12 months
EuroQoL Health questionnaire
The standard analysis for health-related quality of life in cost-effectiveness research, tool in determining Quality adjusted life years (QALYs).
Time frame: 12 months
iMTA Medical Consumption Questionnaire
Collects information on non-disease specific health-care consumption.
Time frame: 12 months
iMTA Productivity Cost Questionnaire
Measurement of productivity loss and work participation.
Time frame: 12 months
Health-care costs
Amount of outpatient clinic visits (visits to medical specialist, supporting staff, other staff), diagnostics (laboratory analyses, imaging), therapy (medication, medical procedures, over the counter medication), general practitioner consultation, medication use prescribed by general practitioner.
Time frame: 12 months
Ran from Feb 2017 to primary completion in Dec 2020, 46 months.
Of 72 non-industry interventional studies with no phase under Rheumatic Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's 46 months is above that.
Counting every sponsor, half of 74 studies reached it within 26 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maasstad Hospital